IFNG and cancer: Human immature myeloid cells from advanced stage cancer patients inhibit allogeneic or tetanus toxoid specific T cell responses [37], while CD14+ myeloid suppressor cells in melanoma patients inhibit polyclonally activated IFN-γ secretion and proliferation of human T cells [38].